Back to Search Start Over

Self-delivery immunological adenosine effector for photodynamic activated immunotherapy against metastatic tumors.

Authors :
Chen, Xiayun
Yan, Mengyi
Liu, Qianqian
Cen, Yi
Yu, Baixue
Yang, Ni
Chen, Ali
Li, Shiying
Source :
Materials & Design. Nov2023, Vol. 235, pN.PAG-N.PAG. 1p.
Publication Year :
2023

Abstract

[Display omitted] • Self-delivery immune adenosine effector (iMade) is fabricated through the self-assembly of pyropheophorbide-a and imaradenant without drug excipients. • Photodynamic therapy of iMade can destroy primary tumor cells to initiate immunogenic cell death (ICD) and trigger the burst release of danger related molecular patterns (DAMPs). • iMade can reduce the recognition of adenosine and A2AR for enhanced antigen presentation to activate anti-tumor immunity. • The activation of systemic immune response can suppress metastatic tumors with low systemic side effects. Therapy-induced immunogenic cell death (ICD) can trigger a burst release of immunostimulatory signals, but some of them can be converted into immunosuppressive factors to extensively restrict systemic anti-tumor immunity. In this work, a self-delivery im mune ad enosine e ffector (designated as iMade) is fabricated to eliminate metastatic tumors via photodynamic activated immunotherapy. Among which, nano-sized iMade is composed of pyropheophorbide-a (Pyro) and imaradenant (AZD) through drug self-assembly without extra excipients. Interestingly, the uniform iMade exhibits favorable stability and dispersity, helping improve the drug delivery efficiency in tumor tissues and cells. Mechanistically, the photodynamic therapy (PDT) of iMade can not only inhibit tumor cell proliferation, but also act as an ICD trigger to induce the burst release of danger related molecular patterns (DAMPs). Successively, AZD is released from iMade to reduce the recognition of adenosine and A2AR for enhanced antigen presentation. Ultimately, iMade is demonstrated to efficiently suppress the growth of primary tumor in vivo , and simultaneously activate systemic immune response to reduce metastatic tumors while cause no obvious systemic side effects. Such a simple but efficient strategy might provide a promising combinatory for spatiotemporal tumor treatment. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02641275
Volume :
235
Database :
Academic Search Index
Journal :
Materials & Design
Publication Type :
Academic Journal
Accession number :
173725591
Full Text :
https://doi.org/10.1016/j.matdes.2023.112378